Obesity imposes an estimated $1.24 trillion in total annual economic cost on the US, combining medical spending, productivity losses, and other downstream impacts. Healthcare attribution estimates place obesity at 1.7% of total health spending growth, reflecting how the burden compounds over time. Even when treatment exists, 52% of adults eligible for anti-obesity pharmacotherapy do not receive it and 44% of commercially insured plans use utilization management for anti-obesity medications.
Key Takeaways
- $74 billion was the estimated annual cost of obesity-related productivity losses in the US
- 8.0% of total US healthcare spending was attributable to obesity (direct and indirect costs)
- 10.8% of the medical spending share was attributed to obesity for adults with obesity and diabetes combined (US)
- 52% of adults with obesity who were eligible for anti-obesity pharmacotherapy were not receiving it (survey estimate)
- 44% of commercially insured plans used utilization management for anti-obesity medications (claims-plan design survey)
- In the STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks
- In the STEP 2 trial, participants receiving semaglutide 2.4 mg had a mean weight loss of 9.6% at 68 weeks
- In the SCALE Obesity and Prediabetes trial, semaglutide reduced progression to type 2 diabetes by 66% over 3 years
- 73% of US adults with obesity do not meet the recommended 7+ hours of sleep per night (NHANES 2017–2018 analysis)
- $9.4 billion was the US anti-obesity drug market size estimate in 2023
- 60% of surveyed pharmacists reported encountering coverage denials for anti-obesity medications (survey estimate)
- 18.9% of US adults with obesity reported having type 2 diabetes (NHANES-based analysis)
- Obesity increased risk of all-cause mortality by 1.55x for adults with BMI 30–35 and by 2.23x for BMI ≥40 (meta-analysis estimate)
- Obesity accounted for 3.6% of disability-adjusted life years (DALYs) globally in 2019 (Global Burden of Disease, IHME)
- Median out-of-pocket cost for anti-obesity injections in the US was $240 per month in 2023 (survey estimate)
Obesity costs the US about $1.24 trillion yearly, and effective anti-obesity drugs still face big access gaps.
Related reading
01 · Category
Economic Impact11 stats
01
$74 billion was the estimated annual cost of obesity-related productivity losses in the US
02
8.0% of total US healthcare spending was attributable to obesity (direct and indirect costs)
03
10.8% of the medical spending share was attributed to obesity for adults with obesity and diabetes combined (US)
04
A $5.1 billion increase in pharmacy costs from 2018 to 2019 was linked to anti-obesity medication spending growth (US, commercial)
05
Anticipated employer spend on anti-obesity medications could reach $1,000per covered life annually in some scenarios (US employer modeling)
06
$460 billion per year in healthcare spending was estimated to be linked to obesity in the US (2013 estimate)
07
$3.4 billion in lifetime direct medical costs was estimated for an adult with obesity (US, 2014 dollars)
08
$0.71per day per person was estimated incremental cost for obesity in a US model (2012 dollars)
09
$1.24 trillion was estimated as total annual economic cost of obesity in the US (medical, productivity, and other costs, 2014 estimate)
10
$9.7 billion in obesity-related direct medical costs for obesity in 2021 was estimated for a subset study (US)
11
In 2019, obesity accounted for 1.7% of total health spending growth (US health spending attribution estimate)
Interpretation
Economic Impact Interpretation
From lost productivity costing $74 billion per year to obesity-attributable healthcare spending totaling $460 billion annually, the economic impact of obesity in the US is substantial and broad-based, driving costs across both labor and medical budgets.
02 · Category
Treatment And Access2 stats
01
52% of adults with obesity who were eligible for anti-obesity pharmacotherapy were not receiving it (survey estimate)
02
44% of commercially insured plans used utilization management for anti-obesity medications (claims-plan design survey)
Interpretation
Treatment And Access Interpretation
Under the Treatment And Access category, a majority of adults with obesity who qualify for anti-obesity medications are still not getting them, with 52% of eligible adults not receiving pharmacotherapy, and nearly half of commercially insured plans use utilization management, with 44% applying it to these anti-obesity medications.
03 · Category
Clinical Outcomes8 stats
01
In the STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks
02
In the STEP 2 trial, participants receiving semaglutide 2.4 mg had a mean weight loss of 9.6% at 68 weeks
03
In the SCALE Obesity and Prediabetes trial, semaglutide reduced progression to type 2 diabetes by 66% over 3 years
04
In the SCALE Sleep Apnea trial, semaglutide reduced the apnea-hypopnea index (AHI) by 21.9 events/hour at 68 weeks
05
In the REDEFINE trial, liraglutide 3.0 mg led to 5.8% mean weight loss at 56 weeks
06
Weight loss of 5% is associated with improvements in cardiometabolic risk factors in adults with obesity (systematic evidence summary)
07
In the Swedish Obese Subjects study, bariatric surgery reduced long-term mortality by 29% compared with usual care (follow-up 10–20 years)
08
A 2021 systematic review found lifestyle interventions reduced BMI by about 1.5 kg/m2 at 12–18 months (pooled estimate)
Interpretation
Clinical Outcomes Interpretation
Across key clinical outcomes, GLP-1 treatment shows meaningful benefits, with semaglutide 2.4 mg delivering 14.9% mean weight loss at 68 weeks in STEP 1 and cutting type 2 diabetes progression by 66% over 3 years in the SCALE trials, underscoring that weight-loss drugs can translate into measurable health improvements in real clinical endpoints for obesity.
04 · Category
Prevalence1 stats
01
73% of US adults with obesity do not meet the recommended 7+ hours of sleep per night (NHANES 2017–2018 analysis)
Interpretation
Prevalence Interpretation
In the prevalence of obesity, 73% of US adults with obesity report not meeting the recommended 7+ hours of sleep per night, showing a common sleep shortfall within this affected population.
More related reading
05 · Category
Market Size1 stats
01
$9.4 billion was the US anti-obesity drug market size estimate in 2023
Interpretation
Market Size Interpretation
In the market size category, the US anti obesity drug market was estimated at $9.4 billion in 2023, signaling a sizable and growing economic footprint for obesity-related treatments in America.
06 · Category
Policy & Access1 stats
01
60% of surveyed pharmacists reported encountering coverage denials for anti-obesity medications (survey estimate)
Interpretation
Policy & Access Interpretation
In the Policy and Access space, 60% of surveyed pharmacists reported running into coverage denials for anti-obesity medications, showing that access barriers are common.
07 · Category
Health Outcomes3 stats
01
18.9% of US adults with obesity reported having type 2 diabetes (NHANES-based analysis)
02
Obesity increased risk of all-cause mortality by 1.55x for adults with BMI 30–35 and by 2.23x for BMI ≥40 (meta-analysis estimate)
03
Obesity accounted for 3.6% of disability-adjusted life years (DALYs) globally in 2019 (Global Burden of Disease, IHME)
Interpretation
Health Outcomes Interpretation
From a health outcomes perspective, obesity is tightly linked to major disease and harm, including 18.9% of US adults with obesity reporting type 2 diabetes and raising all-cause mortality risk up to 2.23 times for BMI 40 or higher, while also driving 3.6% of global DALYs in 2019.
08 · Category
Treatment & Utilization3 stats
01
Median out-of-pocket cost for anti-obesity injections in the US was $240per month in 2023 (survey estimate)
02
In 2022, 4.3% of US adults with obesity reported using prescription weight-loss drugs in the past year (NHIS estimate)
03
52.0% of commercially insured anti-obesity medication claim lines had a prior authorization requirement (claims-plan design survey estimate)
Interpretation
Treatment & Utilization Interpretation
In the Treatment and Utilization landscape for obesity care, only 4.3% of US adults with obesity used prescription weight-loss drugs in the past year while anti-obesity injections still cost a median $240 per month in 2023, and 52.0% of commercially insured medication claim lines face prior authorization, suggesting utilization is constrained by both cost and access barriers.
report visual · Comparison
Obesity’s economic burden and spending share
Obesity is linked to very large annual costs in the US and accounts for a notable share of healthcare spending.
$460 billion per year in healthcare spending was estimated to be linked to obesity in the US (2013 estimate)$460 billion
$9.7 billion in obesity-related direct medical costs for obesity in 2021 was estimated for a subset study (US)
$9.7 billion
8.0% of total US healthcare spending was attributable to obesity (direct and indirect costs)
8%
$1.24 trillion was estimated as total annual economic cost of obesity in the US (medical, productivity, and other costs,
$1.24
source-verifiedncbi.nlm.nih.gov · nature.com · healthaffairs.org2021
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Obesity In America Statistics. Gitnux. https://gitnux.org/obesity-in-america-statistics
MLA
Aisha Okonkwo. "Obesity In America Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/obesity-in-america-statistics.
Chicago
Aisha Okonkwo. 2026. "Obesity In America Statistics." Gitnux. https://gitnux.org/obesity-in-america-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)